These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27266954)

  • 1. Costs and spillover effects of private insurers' coverage of hepatitis C treatment.
    Moreno GA; Mulligan K; Huber C; Linthicum MT; Dreyfus D; Juday T; Marx SE; Gonzalez YS; Brookmeyer R; Lakdawalla DN
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP236-44. PubMed ID: 27266954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of expanding HCV screening and treatment policies in the United States.
    Linthicum MT; Gonzalez YS; Mulligan K; Moreno GA; Dreyfus D; Juday T; Marx SE; Lakdawalla DN; Edlin BR; Brookmeyer R
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP227-35. PubMed ID: 27266953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.
    Rein DB; Borton J; Liffmann DK; Wittenborn JS
    Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
    Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
    Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.
    Moreno GA; Wang A; Sánchez González Y; Díaz Espinosa O; Vania DK; Edlin BR; Brookmeyer R
    Value Health; 2017 Jun; 20(6):736-744. PubMed ID: 28577690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of insurance providers in supporting treatment and management of hepatitis C patients.
    Behzadifar M; Gorji HA; Rezapour A; Behzadifar M; Bragazzi NL
    BMC Health Serv Res; 2019 Jan; 19(1):25. PubMed ID: 30630488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
    Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
    Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of total state coverage for hepatitis C medications.
    Padula WV; Levin JS; Lee J; Anderson GF
    Am J Manag Care; 2021 May; 27(5):e171-e177. PubMed ID: 34002969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare essential: an option to promote better care and curb spending growth.
    Davis K; Schoen C; Guterman S
    Health Aff (Millwood); 2013 May; 32(5):900-9. PubMed ID: 23650323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Rattay T; Dumont IP; Heinzow HS; Hutton DW
    Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The wider public health value of HCV treatment accrued by liver transplant recipients.
    Jena AB; Stevens W; Gonzalez YS; Marx SE; Juday T; Lakdawalla DN; Philipson TJ
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP212-9. PubMed ID: 27266951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating Medicaid patients with hepatitis C: clinical and economic impact.
    Younossi Z; Gordon SC; Ahmed A; Dieterich D; Saab S; Beckerman R
    Am J Manag Care; 2017 Feb; 23(2):107-112. PubMed ID: 28245654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of National Expansion of Insurance Coverage of Medically Tailored Meals With Estimated Hospitalizations and Health Care Expenditures in the US.
    Hager K; Cudhea FP; Wong JB; Berkowitz SA; Downer S; Lauren BN; Mozaffarian D
    JAMA Netw Open; 2022 Oct; 5(10):e2236898. PubMed ID: 36251292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
    Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
    Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.